MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$23,973K
Free Cash flow
$15,035K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of conver...
Payment of issuance costs
Genefab sublease deferred income...
Others
Negative Cash Flow Breakdown
Gain on lease modification
Prepaid expenses and other asset...
Proceeds from cirm grant
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2025-09-30
2025-06-30
Change in fair value-Gene Fab Economic Share
-
0
-
Change in fair value-Gene Fab Option
-
0
-
Loss on sale of property and equipment - related party
-
0
0
Net loss
30,000
-46,971
-
Change in fair value-Gene Fab Notes Receivable
-
0
0
Stock-based compensation
-1,918
1,551
2,730
Depreciation
-1,389
904
1,840
Gain on lease modification
6,762
-
-
Gain on change in fair value of convertible notes - related party-Related Party
271
-
-
Impairment of long-lived assets
-
0
-
Convertible note issuance costs included in net loss - related party-Related Party
300
-
-
Other non-cash charges
13
0
39
Accounts receivable-Nonrelated Party
-311
-12
-
Accounts receivable-Related Party
-666
-49
-
Prepaid expenses and other assets-Related Party
5,901
-4,573
-
Prepaid expenses and other assets-Nonrelated Party
-402
-217
-
Operating lease right-of-use assets
655
-1,687
-
Accounts payable
-1,240
570
-
Accrued expenses and other current liabilities
-1,580
308
-
Operating lease liabilities
699
-3,418
-
Genefab sublease deferred income - related party
2,295
-660
-
Deferred revenue - related party
-32
-
-
Other non-current liabilities
99
0
-
Net cash used in operating activities
14,839
-9,446
-27,123
Proceeds from sale of property and equipment
102
0
12
Purchases of property and equipment
-196
0
196
Net cash provided by (used in) investing activities
298
0
-184
Proceeds from issuance of common stock-A2025ATMAgreement
-
670
-
Proceeds from issuance of convertible notes - related party
9,700
-
-
Payment of issuance costs
-2,444
12
2,457
Taxes paid related to net settlement of stock awards
118
-
-
Proceeds from cirm grant
-2,520
0
2,520
Proceeds from issuance of common stock-Common Stock Purchase Agreement
-
0
-
Proceeds from issuance of common stock related to atm, net of commissions
0
-
534
Net cash provided by financing activities
8,836
124
597
Net decrease in cash, cash equivalents, and restricted cash
23,973
-9,322
-26,710
Cash, cash equivalents, and restricted cash beginning of period
15,783
51,815
-
Cash, cash equivalents, and restricted cash end of period
7,889
15,783
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net loss
$30,000K
Proceeds from issuance of
convertible notes - related...
$9,700K
Purchases of property and
equipment
-$196K
(-200.00%↓ Y/Y)
Proceeds from sale of
property and equipment
$102K
(750.00%↑ Y/Y)
Genefab sublease
deferred income - related...
$2,295K
Operating lease
liabilities
$699K
Accounts
receivable-Related Party
-$666K
Prepaid expenses and
other...
-$402K
Accounts
receivable-Nonrelated Party
-$311K
Convertible note issuance
costs included in net...
$300K
Other non-cash
charges
$13K
(-66.67%↓ Y/Y)
Payment of issuance
costs
-$2,444K
(-199.47%↓ Y/Y)
Net cash used in
operating activities
$14,839K
(154.71%↑ Y/Y)
Net cash provided by
financing activities
$8,836K
(1380.07%↑ Y/Y)
Net cash provided by
(used in) investing...
$298K
(261.96%↑ Y/Y)
Canceled cashflow
$19,847K
Canceled cashflow
$3,308K
Net decrease in
cash, cash...
$23,973K
(189.75%↑ Y/Y)
Gain on lease
modification
$6,762K
Prepaid expenses and
other assets-Related...
$5,901K
Stock-based compensation
-$1,918K
(-170.26%↓ Y/Y)
Accrued expenses and
other current...
-$1,580K
Depreciation
-$1,389K
(-175.49%↓ Y/Y)
Accounts payable
-$1,240K
Operating lease
right-of-use assets
$655K
Gain on change in fair
value of convertible...
$271K
Other non-current
liabilities
$99K
Deferred revenue -
related party
-$32K
Proceeds from cirm grant
-$2,520K
(-200.00%↓ Y/Y)
something is missing
-$670K
Taxes paid related to
net settlement of...
$118K
Buy us a coffee
Senti Biosciences Holdings, Inc. (SNTI)
Senti Biosciences Holdings, Inc. (SNTI)